Oyster Point Pharma, Inc.

NasdaqGS:OYST Stock Report

Market Cap: US$303.2m

Oyster Point Pharma Management

Management criteria checks 4/4

Key information

Jeff Nau

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage20.1%
CEO tenure5.3yrs
CEO ownership0.3%
Management average tenure2.1yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

Is Oyster Point Pharma (NASDAQ:OYST) Using Debt In A Risky Way?

Nov 08
Is Oyster Point Pharma (NASDAQ:OYST) Using Debt In A Risky Way?

Oyster Point's nasal spray to be covered by largest Medicare pharmacy benefit manager

Aug 17

Oyster Point Pharma, Inc. (NASDAQ:OYST) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 14
Oyster Point Pharma, Inc. (NASDAQ:OYST) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Oyster Point stock rises 11% after H.C. Wainwright begins coverage with Buy rating

Jul 18

Oyster Therapeutics: State Of Business Is Confounding

Jun 30

Is Oyster Point Pharma (NASDAQ:OYST) Using Debt In A Risky Way?

Dec 24
Is Oyster Point Pharma (NASDAQ:OYST) Using Debt In A Risky Way?

Oyster Point Pharma (NASDAQ:OYST) Is In A Good Position To Deliver On Growth Plans

Oct 15
Oyster Point Pharma (NASDAQ:OYST) Is In A Good Position To Deliver On Growth Plans

Oyster Point Pharma starts enrollment in mid-stage Neurotrophic Keratopathy study

Jun 21

Here's Why We're Not Too Worried About Oyster Point Pharma's (NASDAQ:OYST) Cash Burn Situation

May 10
Here's Why We're Not Too Worried About Oyster Point Pharma's (NASDAQ:OYST) Cash Burn Situation

Need To Know: Oyster Point Pharma, Inc. (NASDAQ:OYST) Insiders Have Been Buying Shares

Feb 09
Need To Know: Oyster Point Pharma, Inc. (NASDAQ:OYST) Insiders Have Been Buying Shares

Oyster Point Pharma files US application for its lead program in dry eye disease

Dec 18

Companies Like Oyster Point Pharma (NASDAQ:OYST) Are In A Position To Invest In Growth

Dec 18
Companies Like Oyster Point Pharma (NASDAQ:OYST) Are In A Position To Invest In Growth

Oyster Point Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

CEO Compensation Analysis

How has Jeff Nau's remuneration changed compared to Oyster Point Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

-US$177m

Jun 30 2022n/an/a

-US$158m

Mar 31 2022n/an/a

-US$130m

Dec 31 2021US$3mUS$563k

-US$101m

Sep 30 2021n/an/a

-US$81m

Jun 30 2021n/an/a

-US$79m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$6mUS$530k

-US$71m

Sep 30 2020n/an/a

-US$68m

Jun 30 2020n/an/a

-US$63m

Mar 31 2020n/an/a

-US$58m

Dec 31 2019US$4mUS$390k

-US$46m

Sep 30 2019n/an/a

-US$30m

Jun 30 2019n/an/a

-US$25m

Mar 31 2019n/an/a

-US$17m

Dec 31 2018US$390kUS$300k

-US$17m

Compensation vs Market: Jeff's total compensation ($USD2.80M) is about average for companies of similar size in the US market ($USD2.86M).

Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.


CEO

Jeff Nau (47 yo)

5.3yrs

Tenure

US$2,803,339

Compensation

Dr. Jeffrey Nau, also known as Jeff, Ph. D, M. M. S, has been President, Chief Executive Officer and Director at Oyster Point Pharma, Inc since October 2017. Dr. Nau served as Vice President of Clinical an...


Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Nau
President5.3yrsUS$2.80m0.31%
$ 933.1k
Daniel Lochner
CFO & Chief Business Officer3.5yrsUS$1.88m0.20%
$ 605.7k
George Donato
Senior VP of CMC & Operations2.2yrsno datano data
Eric Carlson
Chief Scientific Officer2.1yrsno datano data
Arty Ahmed
VP of Investor relationsno datano datano data
Barry Rosenfeld
Senior VP & General Counsel1.2yrsno datano data
Raegan McClain
Chief Compliance & Privacy Officer1.2yrsno datano data
Karen Castillo-Paff
Vice President of Communications & Public Relationsless than a yearno datano data
Dave Benadon
Chief Human Resources Officerless than a yearno datano data
Loni Da Silva
Senior Vice President of Regulatory Affairs2.2yrsno datano data
Marian Macsai
Chief Medical Officer of Medical Affairs2.1yrsno datano data
Michael Campbell
Senior VP & Head of Commercialless than a yearno datano data

2.1yrs

Average Tenure

Experienced Management: OYST's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Nau
President5.3yrsUS$2.80m0.31%
$ 933.1k
Michael Atieh
Independent Director2.3yrsUS$176.43k0.048%
$ 144.8k
Ali Behbahani
Independent Director5.5yrsUS$207.32k0.037%
$ 112.4k
Aimee Weisner
Independent Director3.3yrsUS$167.49k0.12%
$ 370.7k
Donald Santel
Non-Executive Chairperson1.5yrsUS$354.47k0.012%
$ 35.5k
Mark Murray
Director5.3yrsUS$158.56k0.44%
$ 1.3m
Benjamin Tsai
Independent Director3.9yrsUS$171.43k0.037%
$ 112.4k
Clare Ozawa
Independent Director3.9yrsUS$167.71k0.041%
$ 123.6k
George Eliades
Independent Director1.8yrsUS$553.37k0.043%
$ 131.4k

3.9yrs

Average Tenure

52.5yo

Average Age

Experienced Board: OYST's board of directors are considered experienced (3.9 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.